A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A

Brief description of study

The purpose of the study is to determine the safety and tolerability of investigational treatment combinations with or without pembrolizumab or pembrolizumab alone for the treatment of melanoma. The investigational agents in this study are MK-1308 (anti-CTLA4), MK-7684 (anti-TIGIT), and Lenvatinib. The investigational agents have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.


Clinical Study Identifier: s19-00404
ClinicalTrials.gov Identifier: NCT04305041
Principal Investigator: Janice Mehnert.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.